Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04527328 · ClinicalTrials.gov registry record · NA
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
A NA study, sponsored by Alkahest.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT04527328 is a NA study that has completed, run by Alkahest. The registered enrollment target is 10 participants.
The verdict
NCT04527328, a NA study, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
Interventions
- PROCEDURE Hemodialysis
- DEVICE AKST1210
- OTHER Sham Control (No Intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2021-06-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04527328
The ClinicalTrials.gov registry entry for NCT04527328 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hemodialysis is the first listed.
NCT04527328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04527328 about?
NCT04527328 is a clinical study titled "A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment". This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
What is the current status of trial NCT04527328?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-04-28. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT04527328?
The interventions under investigation include: Hemodialysis (PROCEDURE), AKST1210 (DEVICE), Sham Control (No Intervention) (OTHER).
Who is sponsoring clinical trial NCT04527328?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.